Strempel Nikola, Strehmel Janine, Overhage Joerg
Karlsruhe Institute of Technology (KIT), Institute of Functional Interfaces, PO Box 3640, 76021 Karlsruhe, Germany.
Curr Pharm Des. 2015;21(1):67-84. doi: 10.2174/1381612820666140905124312.
The increasing prevalence of persistent biofilm infections, such as wound infections, chronic lung infections or medical device- related infections, which usually tolerate conventional antibiotic treatment, calls for the development of new therapeutic strategies. To date, antimicrobial peptides (AMPs) are considered as promising agents in the fight against multidrug-resistant bacterial biofilm infections, since many of them have been shown to prevent biofilm formation or even kill preexisting, mature biofilms of several Gram-positive and Gram-negative bacteria in addition to their bactericidal actions to planktonic cells. In this mini-review, we summarize in vitro and in vivo antibiofilm properties of natural and synthetic cationic AMPs against clinically relevant bacterial pathogens. Furthermore, the benefits and challenges in the use of AMPs for the medical treatment of bacterial biofilm infections are discussed.
持续性生物膜感染(如伤口感染、慢性肺部感染或医疗器械相关感染)的患病率不断上升,这些感染通常对传统抗生素治疗具有耐受性,因此需要开发新的治疗策略。迄今为止,抗菌肽(AMPs)被认为是对抗多重耐药细菌生物膜感染的有前景的药物,因为除了对浮游细胞具有杀菌作用外,许多抗菌肽还被证明可以防止生物膜形成,甚至杀死几种革兰氏阳性和革兰氏阴性细菌预先存在的成熟生物膜。在本综述中,我们总结了天然和合成阳离子抗菌肽对临床相关细菌病原体的体外和体内抗生物膜特性。此外,还讨论了使用抗菌肽治疗细菌生物膜感染的益处和挑战。